Innate Immunotherapeutics

Last updated
Innate Immunotherapeutics Limited
IndustryBiotechnology
PredecessorVirionyx
SuccessorAmplia Therapeutics Limited
Headquarters
Sydney
,
Australia [1]
Key people
Simon Wilkinson CEO [1]
Products MIS416
Website https://www.ampliatx.com

Innate Immunotherapeutics (INNM) was a biopharmaceutical company, previously known as Virionyx, with headquarters in Sydney, Australia and a branch in Auckland, New Zealand. Their focus in 2009 was the "development of a new generation of immune response modifier for potential use in the treatment of a range of infectious diseases, certain cancers, and as a novel cellular and humoral adjuvant, " [2] and developed a proprietary multiple sclerosis drug, MIS416. [3] In April 2009 the firm changed its name to Innate Immunotherapeutics to reflect their focus on the development of MIS416, and moved their headquarters from Auckland, New Zealand to Sydney, Australia. [2] On June 22, 2017, Innate Immunotherapeutics announced that the MIS416 clinical trials undertaken to evaluate its efficacy in managing secondary progressive multiple sclerosis (SPMS), [4] [5] [6] [7] had "failed to show any clinically meaningful benefit or statistical significance." [8] These findings resulted in the stocks crashing on the Australian Securities Exchange (ASX). [8]

Contents

Innate Immunotherapeutics received media attention in 2018 after its majority owner US Congressman Chris Collins was arrested for insider trading. [9] In September, 2018, the company changed its name to Amplia Therapeutics Limited. [10]

History

In 2009, Gill Webster, Ph.D., was Innate Therapeutics' chief scientific officer. [2] By 2009, MIS416 had "shown promising activity in preclinical proof-of-principle studies in cancer, infectious and autoimmune diseases [2] In a 2009 article published by BioPharm International, researchers discussed the potential of the then-novel, MIS416 adjuvant as a therapeutic vaccine "for patients with cancer or acquired chronic infections, such as HIV, hepatitis, tuberculosis, and malaria". [3]

MIS416 is "a myeloid-directed microparticle immune response modifier (derived from Cutibacterium acnes ), which was originally developed as a vaccine adjuvant." [11] [12] "MIS416 has been suggested to modulate T-cell-mediated autoimmune responses in EAE by simultaneously activating innate Toll-like receptor 9 and nucleotide-binding oligomerization domain-containing protein 2." [11] [12]

According to White, O'Sullivan, Stone and La Flamme in their January 31, 2014 PLoS One article, the "restricted uptake of MIS416 by phagocytic cells results in targeted modulation of the innate wing of the immune system, which contrasts with soluble agonists, which can directly activate a broader range of innate and adaptive immune subsets". [13] : 9  [11] White, O'Sullivan, Stone and La Flamme also found that MIS416 "[suppressed] the development of proinflammatory T helper (Th)1, Th2, and Th17 cells in EAE, and [increased] the serum levels of IFN-γ and IFN-γ-associated proteins in 19 patients with SPMS." [13] [11]

"MIS416 was initially used in patients with SPMS outside of a formal clinical trial setting under compassionate use legislation in New Zealand." [11]

Shirani also reported in 2016, that a "phase IIb trial [was] underway to further investigate the effect of MIS416 in progressive forms of MS (NCT02228213)". [11] [14]

On June 22, 2017, Innate Immunotherapeutics announced that the MIS416 clinical trials had "failed to show any clinically meaningful benefit or statistical significance." [8] Their stocks immediately crashed on the Australian Securities Exchange (ASX). [8]

On August 31, Innate Immunotherapeutics CEO announced that the firm would be closing over the next few months. [15]

Innate's board of directors included Chairman Warwick Tong, CEO Simon Wilkinson, Robert Peach, Christian Behrenbruch, Christopher Burns, and Andrew J. Cooke. [16]

Chris Collins involvement

Innate Immunotherapeutics's largest stockholder by August 2016, the United States congressman Chris Collins (R-N.Y.), had begun investing in the company in 2002. [17] Over the years Collins raised money for the company and was invited to serve on its board of directors. [17]

In August 2016 Collins purchased 4 million more shares in Innate Immunotherapeutics making him the largest shareholder. At the same time Tom Price, who until 29 September 2017 was the 23rd United States Secretary of Health and Human Services, purchased 400,613 Innate Immunotherapeutics shares valued at $100,000 to $250,000. [6] Senator Ron Wyden (D-Oregon) raised potential concerns about Price's Innate Immunotherapeutics investments which "could be affected by legislation that comes before Congress." [6]

By June 8, 2017, Collins had announced that Innate's drug had just "completed a Phase 2B clinical trial", and Innate Immunotherapeutics "hopes to sell off the product later [in 2017]." [17] On June 22, 2017, Collins learned through a "private email from [Innate Immunotherapeutics]' chief executive that the clinical trials for the "potentially lucrative experimental drug had failed." Collins' son, Cameron Collins, who held Innate Immunotherapeutics shares, avoided over $570,000 in losses by selling his stocks on June 22, after his father had warned him that the Phase 2B clinical trials had failed. [18] By June 8, 2017 the price per share in the United States' over-the-counter (OTC) market of INNMF, had dropped to 58 cents per share". [4] By June 27, it was reported that Collins, who was the largest INNMF stockholder, "incurred a paper loss of nearly $17 million". [8]

In May 2017, White House ethics investigators "began probing Collins for his role in recruiting investors to buy stock in Innate Immunotherapeutics after several complaints were filed". [17] Members of Congress are explicitly barred from trading stocks using insider information." [17] In October 2017, the Office of Congressional Ethics (OCE) said they had "substantial reason" to believe that Collins had improperly used his public office to benefit Innate, and had forwarded nonpublic information to other investors. [19]

On August 8, 2018, Collins, his son Cameron, and Cameron's fiancée's father Stephen Zarsky were arrested on insider trading charges. [20] Collins resigned on October 1, 2019, the day before he pleaded guilty to insider trading. [21] [9] He was sentenced to 26 months in prison, [22] while Cameron was sentenced to probation and community service. [23]

MIS416

MIS416 is a vaccine adjuvant and "immunogen co-delivery system". [3] In 2011, in an NIH publication MIS416 was described as a "non-toxic microparticle adjuvant derived from Propionibacterium acnes comprising immunostimulatory muramyl dipeptide and bacterial DNA promotes cross-priming and Th1 immunity". [24] In 2015, Innate Immunotherapeutics described it as an "immunomodulator" for "patients with chronic progressive multiple sclerosis". [25]

Clinical trials

Innate Immunotherapeutics undertook a 12-month clinical study (NCT02228213) with 13 patients with early funding from the research arm, Fast Forward LLC, of the National MS Society in the U.S. In 2016, the Phase 2B, placebo-controlled clinical trial of MIS416 which includes nine patients from the original trial, was underway. [1] [26] [27] Research on MIS416 is undertaken in collaboration with Raleigh, North Carolina's INC Research under the tenure of CEO Alistair Macdonald. [28]

Renamed to Amplia Therapeutics

On September 5, 2018, Innate Immunotherapeutics changed their name to Amplia Therapeutics (Stock Code ASX: ATX) [29] [30]

Related Research Articles

<span class="mw-page-title-main">Multiple sclerosis</span> Disease that damages the myelin sheaths around nerves

Multiple sclerosis (MS) is an autoimmune disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged. This damage disrupts the ability of parts of the nervous system to transmit signals, resulting in a range of signs and symptoms, including physical, mental, and sometimes psychiatric problems. Symptoms include double vision, vision loss, eye pain, muscle weakness, and loss of sensation or coordination. MS takes several forms, with new symptoms either occurring in isolated attacks or building up over time. In relapsing forms of MS, between attacks, symptoms may disappear completely, although some permanent neurological problems often remain, especially as the disease advances. In progressive forms of MS, bodily function slowly deteriorates once symptoms manifest and will steadily worsen if left untreated.

A cancer vaccine, or oncovaccine, is a vaccine that either treats existing cancer or prevents development of cancer. Vaccines that treat existing cancer are known as therapeutic cancer vaccines or tumor antigen vaccines. Some of the vaccines are "autologous", being prepared from samples taken from the patient, and are specific to that patient.

<span class="mw-page-title-main">Natalizumab</span> Medication used to treat multiple sclerosis and Crohns disease

Natalizumab, sold under the brand name Tysabri among others, is a medication used to treat multiple sclerosis and Crohn's disease. It is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin. It is given by intravenous infusion. The drug is believed to work by reducing the ability of inflammatory immune cells to attach to and pass through the cell layers lining the intestines and blood–brain barrier.

<span class="mw-page-title-main">Cladribine</span> Pharmaceutical drug

Cladribine, sold under the brand name Leustatin, among others, is a medication used to treat hairy cell leukemia and B-cell chronic lymphocytic leukemia. Cladribine, sold under the brand name Mavenclad, is used for the treatment of adults with highly active forms of relapsing-remitting multiple sclerosis.

Tcelna is an anti-T cell vaccine being studied in multiple sclerosis (MS). As of 2016 it is in phase II trials.

<span class="mw-page-title-main">Viral vector</span> Biotechnology to deliver genetic material into a cell

Viral vectors are modified viruses designed to deliver genetic material into cells. This process can be performed inside an organism or in cell culture. Viral vectors have widespread applications in basic research, agriculture, and medicine.

In immunology, an adjuvant is a substance that increases or modulates the immune response to a vaccine. The word "adjuvant" comes from the Latin word adiuvare, meaning to help or aid. "An immunologic adjuvant is defined as any substance that acts to accelerate, prolong, or enhance antigen-specific immune responses when used in combination with specific vaccine antigens."

Neurovax is a vaccine designed to treat patients with multiple sclerosis. Developed by Immune Response BioPharma, Inc. it is currently in phase II clinical trials. Neurovax is designed to stimulate FOXP3+ regulatory T-cells that can then suppress the autoreactive T-cells in some patients.

Research in multiple sclerosis may find new pathways to interact with the disease, improve function, curtail attacks, or limit the progression of the underlying disease. Many treatments already in clinical trials involve drugs that are used in other diseases or medications that have not been designed specifically for multiple sclerosis. There are also trials involving the combination of drugs that are already in use for multiple sclerosis. Finally, there are also many basic investigations that try to understand better the disease and in the future may help to find new treatments.

<span class="mw-page-title-main">Dirucotide</span> Chemical compound

Dirucotide (also known as MBP8298) was developed by two research scientists (Dr. Kenneth G. Warren, MD, FRCP(C) & Ingrid Catz, Senior Scientist) at the University of Alberta for the treatment of Multiple Sclerosis (MS). Dirucotide is a synthetic peptide that consists of 17 amino acids linked in a sequence identical to that of a portion of human myelin basic protein (MBP). The sequence of these 17 amino acids is

A hepatitis C vaccine, a vaccine capable of protecting against the hepatitis C virus (HCV), is not yet available. Although vaccines exist for hepatitis A and hepatitis B, development of an HCV vaccine has presented challenges. No vaccine is currently available, but several vaccines are currently under development.

Adjuvant System 04 or AS04 is a trade name for a combination of adjuvants used in various vaccine products by GlaxoSmithKline, in particular the Fendrix hepatitis B vaccine and Cervarix human papillomavirus (HPV) vaccine. It consists of aluminium hydroxide and monophosphoryl lipid A (MPL). It is the successor of AS03, a squalene based adjuvant used in H1N1/09 and H5N1 influenza vaccines.

Tolerogenic therapy aims to induce immune tolerance where there is pathological or undesirable activation of the normal immune response. This can occur, for example, when an allogeneic transplantation patient develops an immune reaction to donor antigens, or when the body responds inappropriately to self antigens implicated in autoimmune diseases. It must provide absence of specific antibodies for exactly that antigenes.

Eftilagimod alpha is a large-molecule cancer drug being developed by the clinical-stage biotechnology company Immutep. Efti is a soluble version of the immune checkpoint molecule LAG-3. It is an APC Activator used to increase an immune response to tumors, and is administered by subcutaneous injection. Efti has three intended clinical settings:

Viralytics Ltd is an Australian biotechnology company working in the field of oncolytic viruses, that is, viruses that preferentially infect and kill cancer cells. The company's oncolytic virus product, called Cavatak, is currently in clinical trials in metastatic melanoma and other cancers. The drug was granted Orphan Drug status in advanced melanoma in December 2005.

<span class="mw-page-title-main">Siponimod</span> Chemical compound

Siponimod, sold under the brand name Mayzent, is a selective sphingosine-1-phosphate receptor modulator for oral use that is used for multiple sclerosis (MS). It is intended for once-daily oral administration.

There are several ways for pharmaceuticals for treating multiple sclerosis (MS) to reach the market.

Otilimab is a fully human antibody which has been developed by the biotechnology company MorphoSys. It can also be referred to as HuCAL antibody, HuCAL standing for Human Combinatorial Antibody Library and being a technology used to generate monoclonal antibodies. Otilimab is directed against the granulocyte-macrophage colony stimulating factor (GM-CSF), a monomeric glycoprotein functioning as a cytokine promoting both proliferation and activation of macrophages and neutrophils.

MIS416 is an experimental drug developed by Innate Immunotherapeutics which underwent clinical trials to treat secondary progressive multiple sclerosis. It is derived from the bacteria that causes acne and targets myeloid cells through TLR9 and NOD2. In one of its first rounds of clinical trials, the drug was shown to be "safe and well tolerated", with 80% of secondary-progressive multiple sclerosis patients exhibiting more than 30% improvement in at least one area of their MS status. However, Phase II clinical trials were unable to prove that the drug provided a benefit to patients. It is also being researched as a potential treatment for cancer.

A therapeutic vaccine is a vaccine which is administered after a disease or infection has already occurred. A therapeutic vaccine works by activating the immune system of a patient to fight an infection. A therapeutic vaccine differs from a prophylactic vaccine in that prophylactic vaccines are administered to individuals as a precautionary measure to avoid the infection or disease while therapeutic vaccines are administered after the individual is already affected by the disease or infection. A therapeutic vaccine fights an existing infection in the body rather than immunizing the body for protection against future diseases and infections. Therapeutic vaccines are mostly used against viral infections. Patients affected with chronic viral infections are administered with therapeutic vaccines, as their immune system is not able to produce enough efficient antibodies.

References

  1. 1 2 3 Semedo, Daniela (April 15, 2016). "Innate Immunotherapeutics Fully Enrolls Phase 2 Study of Drug Candidate to Treat SPMS". Multiple Sclerosis News Today. Retrieved August 8, 2018.
  2. 1 2 3 4 Virionyx Changes Name to Innate Therapeutics, Advances Novel Immune Stimulant, MIS416, to Clinical Trials, Auckland, New Zealand, April 17, 2009, retrieved January 24, 2017{{citation}}: CS1 maint: location missing publisher (link) Contact Joan E. Kureczka, Kureczka/Martin Associates, MSEM Founder and Principal and the Vivant Group, San Francisco, California
  3. 1 2 3 Gill A. Webster; Frank B. Gelder (January 2, 2009), "The Therapeutic Vaccine Potential of MIS416 Adjuvant: Linking innate and adaptive immunity through the activation of multiple innate host defenses", BioPharm International, BioPharm International Supplements, 2009 Supplement (1), retrieved January 24, 2017
  4. 1 2 "Innate Immunotherapeutics Ltd Stock Chart (INNMF)", NASDAQ, January 24, 2017, retrieved January 24, 2017
  5. ↑ Kaplan, Thomas; Rappeport, Alan; Huetteman, Emmarie (January 24, 2017). "Trump's Health Nominee Defends Stock Deals as 'Ethical, Above Board, Legal and Transparent'". New York Times. Retrieved January 24, 2017.
  6. 1 2 3 Katie Thomas (January 24, 2017), "Australian Drug Maker Has Low Profile but Powerful Backers in Washington", The New York Times , retrieved January 24, 2017
  7. ↑ Bill 4848, US Congress, March 2016, retrieved January 24, 2017, introduced by Tom Price(R-GA-6) on March 23, 2016 to House Energy and Commerce Committees: House - Energy and Commerce; Ways and Means Latest Action:03/30/2016 Referred to the Subcommittee on Health on March 30, 2016
  8. 1 2 3 4 5 LaMotta, Lisa (June 27, 2017). "Innate becomes the latest loser in MS". BioPharma Dive. Retrieved August 8, 2018.
  9. 1 2 "Behind the Collins scandal: How one phone call devastated two families". The Buffalo News. 2020-01-13. Retrieved 2020-01-24.
  10. ↑ "Announcements and Reports | Amplia Therapeutics Limited". www.ampliatx.com. Retrieved 2020-04-16.
  11. 1 2 3 4 5 6 Shirani, Afsaneh; Okuda, Darin T.; Stüve1, Olaf (January 2016). "Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis". Neurotherapeutics. 3 (1): 58–69. doi:10.1007/s13311-015-0409-z. PMC   4720678 . PMID   26729332.{{cite journal}}: CS1 maint: numeric names: authors list (link)
  12. 1 2 96. Girvan RC, Knight DA, O'Loughlin CJ, Hayman CM, Hermans IF, Webster GA. MIS416, a non-toxic microparticle adjuvant derived from Propionibacterium acnes comprising immunostimulatory muramyl dipeptide and bacterial DNA promotes cross-priming and Th1 immunity. Vaccine. 2011;29:545–557. doi : 10.1016/j.vaccine.2010.10.040
  13. 1 2 Madeleine, White; Webster, Gill; O'Sullivan, David; Stone, Sarrabeth; La Flamme, Anne Camille (January 31, 2014). "Targeting innate receptors with MIS416 reshapes Th responses and suppresses CNS disease in a mouse model of multiple sclerosis". PLOS ONE. 9 (1): e87712. Bibcode:2014PLoSO...987712W. doi: 10.1371/journal.pone.0087712 . PMC   3909208 . PMID   24498172. [PMC free article] [PubMed] [Cross Ref]
  14. ↑ "MIS416", Innate Immunotherapeutics, archived from the original on August 14, 2015, retrieved June 14, 2015
  15. ↑ "Innate Immunotherapeutics faces closure: CEO Simon Wilkinson". The Australian . August 31, 2017.
  16. ↑ "Investors Fact Sheet". Innate Immunotherapeutics Limited. North Melboure. nd. Retrieved August 8, 2018.
  17. 1 2 3 4 5 Wong, Scott (June 8, 2017). "Exclusive: GOP lawmaker talked stocks with colleagues" . Retrieved June 8, 2017. The Buffalo News reported that many in the [Buffalo]'s business elite had bought stock in the drug company after hearing from Collins...Collins first invested in Innate Immunotherapeutics, which has developed a drug to fight advanced multiple sclerosis, about 15 years ago. He said he's raised money for the company during tough times and has earned a spot on its board of directors...[In August 2016, Collins] purchased an additional 4 million shares. On [January 27, 2017] the stock hit an all-time high of $1.83 per share, but it was trading at 74 cents per share on [May 7, 2017].
  18. ↑ Feuer, Alan; Goldmacher, Shane (August 8, 2018). "New York Congressman Chris Collins Is Charged With Insider Trading". The New York Times. Retrieved August 8, 2018.
  19. ↑ Tau, Byron (October 12, 2017). "Congressional Ethics Office Says New York Republican May Have Violated Law". Wall Street Journal. ISSN   0099-9660 . Retrieved August 8, 2018.
  20. ↑ Breuninger, Kevin (August 8, 2018). "New York GOP Rep. Chris Collins to be indicted on insider trading charges". CNBC. Retrieved August 8, 2018.
  21. ↑ "The Latest: Speaker Pelosi's office says Collins resigning". AP NEWS. September 30, 2019. Retrieved September 30, 2019.
  22. ↑ Zremski, Jerry (January 17, 2020). "An anguished Chris Collins faces 26 months in prison". The Buffalo News . Retrieved January 17, 2020.
  23. ↑ "Son of former Congressman Chris Collins sentenced to 5 years of probation". WGRZ. 23 January 2020. Retrieved 2020-01-24.
  24. ↑ Girvan RC, Knight DA, O'Loughlin CJ, Hayman CM, Hermans IF, Webster GA (January 10, 2011). "MIS416, a non-toxic microparticle adjuvant derived from Propionibacterium acnes comprising immunostimulatory muramyl dipeptide and bacterial DNA promotes cross-priming and Th1 immunity". Vaccine . 29 (3): 545–57. doi:10.1016/j.vaccine.2010.10.040. PMID   21034827.
  25. ↑ Luckey, Alison M; Anderson, Tim; Silverman, Michael H; Webster, Gill (January 2015). "Safety, tolerability and pharmacodynamics of a novel immunomodulator, MIS416, in patients with chronic progressive multiple sclerosis". Multiple Sclerosis Journal: Experimental, Translational and Clinical. 1: 2055217315583385. doi:10.1177/2055217315583385. PMC   5433401 . PMID   28607691.
  26. ↑ "Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis". United States Library of Medicine (NIH). Clinical trials (NCT02228213). July 14, 2017. Retrieved August 8, 2018.
  27. ↑ Dutt, Streetama (July 17, 2017). "MIS416 for Secondary Progressive Multiple Sclerosis". Multiple Sclerosis News Today via BioNews Services . Dallas, Texas. Retrieved August 8, 2018.
  28. ↑ "INC Research". INCR (NASDAQ)]. Raleigh, North Carolina. According to SEC filings, INCR CEO Alistair Macdonald, who established INC Research in October 1, 2016, holds $2,669,127 in company stocks after selling shares worth $69,437.50 on January 20, 2017.(NASDAQ:INCR)
  29. ↑ "Amplia Announcement".
  30. ↑ "Share Price & Information - ASX". www.asx.com.au. Retrieved 2020-04-16.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.